Tag:Cancer

Chinese Pharma Companies Pushing for Global Reach with focus on R&D

In targeted therapies, drugs are used to “target” cancerous cells without having an adverse impact on normal cells during cancer treatments. In...

Coherus to move beyond biosimilars with a cancer immunotherapy drug

Coherus Biosciences, known for developing biosimilars, had decided to extend its objectives in February.  The company has now stepped into developing innovative...

Amgen to buy Teneobio for $2.5B to further its antibody interests

Amgen isn’t leaning on its laurels even after getting a prompt approval for its carefully manufactured KRAS lung cancer drug, Lumakras, as...

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

Bristol-Myers Squibb and Agenus enter a $1.56bn definitive agreement to support cancer programme

An exclusive international license contract of $1.56 billion has been signed between BMS (Bristol Myers Squibb) and Agenus, for AGEN1777

Latest news

Roche offers $50 billion to US pharma production in response to the tariff threat

Roche, the drugmaker giant, announced its interest in investing $50 billion over five years in new and existing facilities...
- Advertisement -

Biolinq Secures $100 Million to Advance Glucose Biosensor and Expand Commercialization Plans

Biolinq has announced the successful closure of a $100 million venture capital investment round aimed at finalizing the development...

VelaVigo Bio Strikes Second Major Licensing Agreement, Transfers Bispecific Rights to Ollin Biosciences

In a continued series of strategic moves, VelaVigo Bio, a biotechnology firm based in Shanghai, has finalized its second...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm